{
  "docId": "019de073-e127-72a6-a95e-e417b3ed6013",
  "docSlug": "0a46c3e8bf46013b57087adaac7a88f4",
  "documentTitle": "Xeris Biopharma | Investor Presentation Deck | 11 slides",
  "authorId": "xeris-biopharma",
  "authorName": "Xeris Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 11,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e127-72a6-a95e-e417b3ed6013/5",
  "deckHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013",
  "deckJsonHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013.json",
  "deckAnchorHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.045,
        "y": 0.24
      },
      "kind": "list",
      "text": "Background: Reliance on FDA findings for Synthroid; Single 600 ug dose comparison; Three ascending doses of XP-8121 SC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16a7f1fe-0a1d-476c-861b-f388f79b6062",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.045,
        "y": 0.66
      },
      "kind": "list",
      "text": "Chronic Dosing Simulations: Compare steady state exposure; Determine dose conversion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "925b0cf8-ee29-423c-bd7c-e8a89872c75f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.045,
        "y": 0.45
      },
      "kind": "list",
      "text": "Study Objectives: Characterize pharmacokinetics; Evaluate dose proportionality; Assess safety and tolerability.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b5bf4df-c5d8-466a-b16e-e94e84d36bd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.39,
        "x": 0.045,
        "y": 0.12
      },
      "kind": "title",
      "text": "XP-8121-108: Study Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43106cd0-a9d7-4c64-8d0d-fc3861a0aaa7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "62ad1468-8377-4585-b87a-28092f94db55",
      "evidence": "list/bullet: Study Objectives: Characterize pharmacokinetics; Evaluate dose proportionality; Assess safety and tolerability.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "af072837-2b90-4168-8f35-e24f021b1e1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The appendix methodology slides describe the product and study design.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f2a7b48c-76f2-4134-b42d-4dd72dd13ce4",
      "evidence": "The appendix methodology and key takeaways slides present the golden circle.",
      "position": 1,
      "objective": "How does XeriSol™ Levothyroxine work and what are the benefits?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}